Triomics Revolutionizes Cancer Care with GenAI
May 10, 2024, 9:44 pm
Location: Ukraine, Kyiv
Employees: 1-10
Founded date: 2016
Total raised: $15M
Triomics, a trailblazing company in the realm of cancer care, has recently secured a whopping $15 million in funding from big players in Silicon Valley like Lightspeed, Nexus Venture Partners, General Catalyst, and Y Combinator. Founded by Sarim Khan and Hrituraj Singh, Triomics is on a mission to transform oncology workflows using the power of generative AI.
Triomics partners with renowned academic cancer centers and researchers to develop cutting-edge generative AI benchmarks and best practices. By collaborating with organizations like the Collaboration for Oncology-focused LLM Training (COLT) and the Cancer Informatics for Cancer Centers (CI4CC) Society, Triomics is at the forefront of innovation in the field of cancer care.
The current landscape of oncology workflows is riddled with challenges. Manual data analysis is time-consuming, leading to delays in patient care, backlogs, and provider burnout. Triomics recognized these pain points and set out to revolutionize the way cancer care is delivered.
Enter OncoLLM™, Triomics' groundbreaking generative AI model trained specifically on oncology data. This innovative technology can identify eligible clinical trial patients in a matter of minutes, extract data from unstructured notes with unparalleled accuracy, and outperform other retrieval models by a significant margin.
Triomics' software suite, powered by OncoLLM™, seamlessly integrates with existing electronic health record (EHR) systems used by hospitals. This integration enables functionalities like Triomics Prism, which automates patient-trial matching, and Triomics Harmony, which supports quality reporting, cohort analysis, and personalized cancer care.
Looking ahead, Triomics plans to further research the efficacy of OncoLLM™ across diverse patient populations and healthcare settings. The company is also focused on developing software that can power additional use cases, solidifying its position as a leader in the realm of cancer care innovation.
In a statement regarding the recent funding, Hrituraj Singh emphasized the deliberate investments made by Triomics in merging expertise in AI research and clinical oncology. This unique blend of skills has allowed Triomics to create software that not only leverages advanced AI models but also addresses potential flaws with a deep understanding of the intricacies of cancer research and care.
Triomics is not just a company; it's a beacon of hope in the fight against cancer, using the power of GenAI to revolutionize the way we approach oncology workflows and ultimately improve patient outcomes.
Triomics partners with renowned academic cancer centers and researchers to develop cutting-edge generative AI benchmarks and best practices. By collaborating with organizations like the Collaboration for Oncology-focused LLM Training (COLT) and the Cancer Informatics for Cancer Centers (CI4CC) Society, Triomics is at the forefront of innovation in the field of cancer care.
The current landscape of oncology workflows is riddled with challenges. Manual data analysis is time-consuming, leading to delays in patient care, backlogs, and provider burnout. Triomics recognized these pain points and set out to revolutionize the way cancer care is delivered.
Enter OncoLLM™, Triomics' groundbreaking generative AI model trained specifically on oncology data. This innovative technology can identify eligible clinical trial patients in a matter of minutes, extract data from unstructured notes with unparalleled accuracy, and outperform other retrieval models by a significant margin.
Triomics' software suite, powered by OncoLLM™, seamlessly integrates with existing electronic health record (EHR) systems used by hospitals. This integration enables functionalities like Triomics Prism, which automates patient-trial matching, and Triomics Harmony, which supports quality reporting, cohort analysis, and personalized cancer care.
Looking ahead, Triomics plans to further research the efficacy of OncoLLM™ across diverse patient populations and healthcare settings. The company is also focused on developing software that can power additional use cases, solidifying its position as a leader in the realm of cancer care innovation.
In a statement regarding the recent funding, Hrituraj Singh emphasized the deliberate investments made by Triomics in merging expertise in AI research and clinical oncology. This unique blend of skills has allowed Triomics to create software that not only leverages advanced AI models but also addresses potential flaws with a deep understanding of the intricacies of cancer research and care.
Triomics is not just a company; it's a beacon of hope in the fight against cancer, using the power of GenAI to revolutionize the way we approach oncology workflows and ultimately improve patient outcomes.